Seleniso will be included in medical insurance in 2024, and patients’ medication costs will be significantly reduced.

Selinexor (Selinexor), an innovative drug that has been marketed in China and is distributed under the name of Selinexor Tablets, has recently received a piece of good news. It has been officially included in the medical insurance catalog by the National Medical Insurance Bureau. This means that the majority of patients can enjoy the benefits of the medical insurance policy when purchasing this drug in medical institutions or retail pharmacies. Due to differences in reimbursement rates from local medical insurance, the actual price paid by patients may vary.

Selinexor is an anti-cancer drug for multiple myeloma. Its main active ingredient isselinexor. After a rigorous clinical trial and approval process, selinesol was approved for use in combination with bortezomib and dexamethasone, providing a new treatment option for adult patients who have experienced at least one prior treatment. Selinisol's combination therapy has also demonstrated significant clinical benefit in patients with severe disease who have worsened since their last treatment.

As for the specific reimbursement conditions for selinesol after being included in medical insurance, the policy stipulates that it is limited to adult patients with relapsed or refractory multiple myeloma who have received previous treatment and have failed to respond to multiple drugs such as proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies. According to relevant sources, the price of each box of Seleniso after being included in medical insurance may be more than 20,000 yuan. However, after eligible patients are reimbursed through medical insurance, the actual burden will be greatly reduced. Those patients who are not eligible for reimbursement can only bear the entire cost themselves.

The domestic launch of the original Seleniso drug and its subsequent medical insurance coverage have undoubtedly brought huge benefits to domestic patients. Although the price of this drug in overseas markets is relatively high, more affordable generic drug options have emerged in overseas markets. Their drug ingredients are basically the same as the original drugs, and the market price may only be more than 2,000 yuan.